微芯生物：CS231295临床试验申请获美国FDA批准

Core Viewpoint - Microchip Biotech (688321) announced that its wholly-owned subsidiary, Microchip Biotech (USA) LLC, received notification from the FDA on July 31, allowing the company to initiate a Phase I clinical trial for its self-developed CS231295 targeting advanced solid tumors [1] Group 1 - The FDA has granted permission for the Phase I clinical trial of CS231295 [1] - The trial is focused on treating advanced solid tumors [1] - The notification was received on July 31 [1]